Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis
Authors
Keywords
Progressive Multifocal Leukoencephalopathy, Natalizumab, Progressive Multifocal Leukoencephalopathy, John Cunningham Virus, Natalizumab Treatment
Journal
CNS DRUGS
Volume 28, Issue 7, Pages 641-648
Publisher
Springer Nature
Online
2014-06-19
DOI
10.1007/s40263-014-0168-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- JC virus antibody status underestimates infection rates
- (2013) Joseph R. Berger et al. ANNALS OF NEUROLOGY
- A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification
- (2013) Peter Lee et al. JOURNAL OF CLINICAL VIROLOGY
- Molecular epidemiology of JCV genotypes in patients and healthy subjects from Northern Italy
- (2013) Nunzia Zanotta et al. JOURNAL OF MEDICAL VIROLOGY
- Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab
- (2013) Jerry Lin et al. JOURNAL OF NEUROIMMUNOLOGY
- Changes to anti-JCV antibody levels in a Swedish national MS cohort
- (2013) Clemens Warnke et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients
- (2013) N. Schwab et al. NEUROLOGY
- Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis
- (2013) C. Warnke et al. NEUROLOGY
- PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section
- (2013) J. R. Berger et al. NEUROLOGY
- JC Viremia in Natalizumab-Treated Patients with Multiple Sclerosis
- (2013) Eugene O. Major et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study
- (2013) Anna Bellizzi et al. Virology Journal
- Lessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis Treated With Natalizumab
- (2013) Aaron L. Boster et al. JAMA Neurology
- Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy
- (2012) Tarek A. Yousry et al. ANNALS OF NEUROLOGY
- Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification
- (2012) A. Laroni et al. Journal of Neuroimmune Pharmacology
- Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group”
- (2012) J Havla et al. Multiple Sclerosis Journal
- Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab
- (2012) Per Soelberg Sørensen et al. Multiple Sclerosis Journal
- Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Gary Bloomgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
- (2012) Molly R. Perkins et al. PLoS Pathogens
- Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: Baseline results of STRATIFY-1
- (2011) Carmen Bozic et al. ANNALS OF NEUROLOGY
- Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma
- (2011) Tatiana Plavina et al. JOURNAL OF CLINICAL VIROLOGY
- Pathogenesis of Progressive Multifocal Leukoencephalopathy—Revisited
- (2011) Martyn K. White et al. JOURNAL OF INFECTIOUS DISEASES
- Sequencing and Analysis of JC Virus DNA From Natalizumab-Treated PML Patients
- (2011) Carl E. Reid et al. JOURNAL OF INFECTIOUS DISEASES
- Progressive Multifocal Leukoencephalopathy (PML) Development Is Associated With Mutations in JC Virus Capsid Protein VP1 That Change Its Receptor Specificity
- (2011) Leonid Gorelik et al. JOURNAL OF INFECTIOUS DISEASES
- Anti-JC virus antibodies: Implications for PML Risk Stratification
- (2010) Leonid Gorelik et al. ANNALS OF NEUROLOGY
- Prevalence of Polyomavirus BK and JC Infection and Replication in 400 Healthy Blood Donors
- (2009) Adrian Egli et al. JOURNAL OF INFECTIOUS DISEASES
- Seroepidemiology of Human Polyomaviruses
- (2009) Jaime M. Kean et al. PLoS Pathogens
- Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA
- (2008) E Iacobaeus et al. Multiple Sclerosis Journal
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started